aibioHRGN Harvard Apparatus Regenerative Technology, Inc.
Harvard Apparatus Regenerative Technology (HRGN) news
Harvard Apparatus Regenerative Technology, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker HRGN, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Harvard Apparatus Regenerative Technology news
We have not published a story on Harvard Apparatus Regenerative Technology yet. When there is news, it will appear here.
Harvard Apparatus Regenerative Technology annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.7 million | $2.3 million |
| Net income (loss) | -$6.9 million | -$7.7 million |
| Cash from operations | -$3.8 million | -$4.9 million |
| Cash and equivalents | $1.4 million | $2.5 million |
Questions about Harvard Apparatus Regenerative Technology
What is the ticker symbol of Harvard Apparatus Regenerative Technology?
Harvard Apparatus Regenerative Technology, Inc. trades under the ticker HRGN on OTC.
Where is Harvard Apparatus Regenerative Technology listed?
Harvard Apparatus Regenerative Technology, Inc. is listed on OTC.
Which country or territory is Harvard Apparatus Regenerative Technology listed under?
Our directory records Harvard Apparatus Regenerative Technology, Inc. under United States.
Does aibio.space cover Harvard Apparatus Regenerative Technology?
aibio.space lists Harvard Apparatus Regenerative Technology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Is Harvard Apparatus Regenerative Technology profitable?
Harvard Apparatus Regenerative Technology, Inc. reported a net loss of $6.9 million for the fiscal year ended Dec 31, 2025, and used $3.8 million of cash in operations, per its annual report to the SEC.
How much does Harvard Apparatus Regenerative Technology spend on research and development?
$2.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Harvard Apparatus Regenerative Technology have?
$351,000 in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: Harvard Apparatus Regenerative Technology
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
Listing details
- Company
- Harvard Apparatus Regenerative Technology, Inc.
- Ticker
- HRGN
- Listing
- OTC
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction